{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:50Z","timestamp":1781650670457,"version":"3.54.5"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>Orthocoronavirinae<\/jats:italic>\n                      virus subfamily (CoV) poses a continuous global health threat. Seven CoV species are known to infect humans and additional animal CoVs with potential for human spillover have been identified. Currently, antiviral drugs are available only against SARS-CoV-2, underscoring the need for broad-spectrum antivirals. Targeting the viral RNA genome with small interfering RNAs (siRNAs) induces its degradation by endogenous nucleases and represents an effective strategy to inhibit CoV replication. Previous studies have demonstrated the efficacy and feasibility of this approach against individual CoV species. However, its potential to serve as a broad-spectrum antiviral strategy effective across multiple members of the CoV subfamily has not been systematically explored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The conservation of all potential siRNA target sites within the CoV genome (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009\u2248\u200930,000) was analyzed using a custom database comprising 250,000 full-length genome sequences from 44 CoV species isolated from diverse mammalian and avian hosts. Antiviral activity of selected siRNA candidates was screened using a replication-competent recombinant SARS-CoV-2 expressing green fluorescent protein. The effect of target site mismatches was assessed using luciferase reporters, and cross-species antiviral activity was evaluated against six representative wild-type CoVs. Cellular toxicity was investigated by monitoring cell death, confluence, metabolic activity, and in silico prediction of siRNA off-target activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Conservation of potential siRNA target sites correlated with the evolutionary distance between CoV species. Several genomic regions were conserved across different CoV subgenera and genera, but no site was universally preserved across all 44 analyzed species. The antiviral activity and tolerability of 347 siRNAs targeting the most promising sites were evaluated in multiple screening rounds. Following optimization of siRNA design and chemistry, we identified a lead candidate, si117m, which displayed high tolerability and potent silencing activity at picomolar concentrations against target sites of SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-OC43 and HCoV-HKU1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study demonstrates the potential of comparative genomics for developing broad-spectrum antiviral siRNAs. We identified a lead siRNA, si117m, which combines a favorable safety profile with cross-species activity against five human CoVs, supporting its potential for clinical translation and future pandemic preparedness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-026-01659-1","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:45:09Z","timestamp":1776818709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative genomics identifies small interfering RNA with activity against all five human betacoronaviruses"],"prefix":"10.1186","volume":"18","author":[{"given":"Julian","family":"Vogler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhankar","family":"Ambike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stoyan","family":"Velkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Chin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Neubecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Fischhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Martan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Sauerhering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"von Brunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Michler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1659_CR1","doi-asserted-by":"publisher","first-page":"D708","DOI":"10.1093\/nar\/gkx932","volume":"46","author":"EJ Lefkowitz","year":"2018","unstructured":"Lefkowitz EJ, et al. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res. 2018;46:D708\u201317. https:\/\/doi.org\/10.1093\/nar\/gkx932.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s44149-021-00005-9","volume":"1","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Qiu Y, Ge X. The taxonomy, host range and pathogenicity of coronaviruses and other viruses in the Nidovirales order. Anim Dis. 2021;1:5. https:\/\/doi.org\/10.1186\/s44149-021-00005-9.","journal-title":"Anim Dis"},{"key":"1659_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jmv.26362","volume":"93","author":"A Veiga","year":"2021","unstructured":"Veiga A, et al. More than just a common cold: Endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults. J Med Virol. 2021;93:1002\u20137. https:\/\/doi.org\/10.1002\/jmv.26362.","journal-title":"J Med Virol"},{"key":"1659_CR4","doi-asserted-by":"publisher","unstructured":"Forni D, et al. Dating the Emergence of Human Endemic Coronaviruses. Viruses. 2022;14. https:\/\/doi.org\/10.3390\/v14051095.","DOI":"10.3390\/v14051095"},{"key":"1659_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41577-022-00809-x","volume":"23","author":"SM Murray","year":"2023","unstructured":"Murray SM, et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat Rev Immunol. 2023;23:304\u201316. https:\/\/doi.org\/10.1038\/s41577-022-00809-x.","journal-title":"Nat Rev Immunol"},{"key":"1659_CR6","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra032498","volume":"349","author":"JS Peiris","year":"2003","unstructured":"Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349:2431\u201341. https:\/\/doi.org\/10.1056\/NEJMra032498.","journal-title":"N Engl J Med"},{"key":"1659_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12879-019-3987-2","volume":"19","author":"K Mobaraki","year":"2019","unstructured":"Mobaraki K, Ahmadzadeh J. Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study. BMC Infect Dis. 2019;19:351. https:\/\/doi.org\/10.1186\/s12879-019-3987-2.","journal-title":"BMC Infect Dis"},{"key":"1659_CR8","unstructured":"World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard > More resources [Dashboard]. https:\/\/data.who.int\/dashboards\/covid19\/more-resources."},{"key":"1659_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13643-024-02476-6","volume":"13","author":"A Faramarzi","year":"2024","unstructured":"Faramarzi A, et al. The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis. Syst Rev. 2024;13:68. https:\/\/doi.org\/10.1186\/s13643-024-02476-6.","journal-title":"Syst Rev"},{"key":"1659_CR10","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery VD, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21:1508\u201313. https:\/\/doi.org\/10.1038\/nm.3985.","journal-title":"Nat Med"},{"key":"1659_CR11","doi-asserted-by":"publisher","first-page":"26915","DOI":"10.1073\/pnas.2001046117","volume":"117","author":"CE Edwards","year":"2020","unstructured":"Edwards CE, et al. Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. Proc Natl Acad Sci U S A. 2020;117:26915\u201325. https:\/\/doi.org\/10.1073\/pnas.2001046117.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1659_CR12","doi-asserted-by":"publisher","first-page":"e0011923","DOI":"10.1128\/cmr.00119-23","volume":"37","author":"D Focosi","year":"2024","unstructured":"Focosi D, Franchini M, Maggi F, Shoham S. COVID-19 therapeutics. Clin Microbiol Rev. 2024;37:e0011923. https:\/\/doi.org\/10.1128\/cmr.00119-23.","journal-title":"Clin Microbiol Rev"},{"key":"1659_CR13","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2022.01.024","volume":"30","author":"J Becker","year":"2022","unstructured":"Becker J, et al. Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV\/RNAi expression vectors. Mol Ther. 2022;30:2005\u201323. https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.024.","journal-title":"Mol Ther"},{"key":"1659_CR14","doi-asserted-by":"publisher","unstructured":"Anglero-Rodriguez YI, et al. High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination. Nucleic Acids Res. 2025;53. https:\/\/doi.org\/10.1093\/nar\/gkae1195.","DOI":"10.1093\/nar\/gkae1195"},{"key":"1659_CR15","unstructured":"US_Department_of_Health_&_Human_Services. Bamlanivimab\/etesevimab. Public Health Emerg (2022). https:\/\/doi.org\/https:\/\/www.phe.gov\/emergency\/events\/COVID19\/investigation-MCM\/Bamlanivimab-etesevimab\/Pages\/default.aspx"},{"key":"1659_CR16","unstructured":"US_Department_of_Health_&_Human_Services. REGEN-COV. Public Health Emerg. 2022. https:\/\/doi.org\/https:\/\/www.phe.gov\/emergency\/events\/COVID19\/investigation-MCM\/cas_imd\/Pages\/default.aspx."},{"key":"1659_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.15252\/emmm.201506172","volume":"8","author":"T Michler","year":"2016","unstructured":"Michler T, et al. Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol Med. 2016;8:1082\u201398. https:\/\/doi.org\/10.15252\/emmm.201506172.","journal-title":"EMBO Mol Med"},{"key":"1659_CR18","doi-asserted-by":"publisher","unstructured":"Michler T et al. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. Gastroenterology 158, 1762\u20131775.e1769 (2020). https:\/\/doi.org\/10.1053\/j.gastro.2020.01.032","DOI":"10.1053\/j.gastro.2020.01.032"},{"key":"1659_CR19","doi-asserted-by":"publisher","first-page":"e2001650","DOI":"10.1002\/adhm.202001650","volume":"10","author":"A Mehta","year":"2021","unstructured":"Mehta A, Michler T, Merkel OM. siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies? Adv Healthc Mater. 2021;10:e2001650. https:\/\/doi.org\/10.1002\/adhm.202001650.","journal-title":"Adv Healthc Mater"},{"key":"1659_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806\u201311.","journal-title":"Nature"},{"key":"1659_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00253-007-0984-y","volume":"76","author":"A Aigner","year":"2007","unstructured":"Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol. 2007;76:9\u201321. https:\/\/doi.org\/10.1007\/s00253-007-0984-y.","journal-title":"Appl Microbiol Biotechnol"},{"key":"1659_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/418244a","volume":"418","author":"GJ Hannon","year":"2002","unstructured":"Hannon GJ. RNA interference. Nature. 2002;418:244\u201351. https:\/\/doi.org\/10.1038\/418244a.","journal-title":"Nature"},{"key":"1659_CR23","unstructured":"Padda IS, Mahtani AU, Patel P, et al. Small Interfering RNA (siRNA) Therapy. StatPearls. Treasure Island: StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580472\/."},{"key":"1659_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","volume":"35","author":"J Gottlieb","year":"2016","unstructured":"Gottlieb J, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transpl. 2016;35:213\u201321. https:\/\/doi.org\/10.1016\/j.healun.2015.08.012.","journal-title":"J Heart Lung Transpl"},{"key":"1659_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-chembioeng-061010-114133","volume":"2","author":"KA Whitehead","year":"2011","unstructured":"Whitehead KA, Dahlman JE, Langer RS, Anderson DG. Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng. 2011;2:77\u201396. https:\/\/doi.org\/10.1146\/annurev-chembioeng-061010-114133.","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"1659_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nbt1081","volume":"23","author":"AD Judge","year":"2005","unstructured":"Judge AD, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457\u201362. https:\/\/doi.org\/10.1038\/nbt1081.","journal-title":"Nat Biotechnol"},{"key":"1659_CR27","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","volume":"52","author":"JA Kulkarni","year":"2019","unstructured":"Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. Acc Chem Res. 2019;52:2435\u201344. https:\/\/doi.org\/10.1021\/acs.accounts.9b00368.","journal-title":"Acc Chem Res"},{"key":"1659_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1021\/ar200110p","volume":"45","author":"OM Merkel","year":"2012","unstructured":"Merkel OM, Kissel T. Nonviral pulmonary delivery of siRNA. Acc Chem Res. 2012;45:961\u201370. https:\/\/doi.org\/10.1021\/ar200110p.","journal-title":"Acc Chem Res"},{"key":"1659_CR29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jconrel.2022.03.051","volume":"345","author":"D Baldassi","year":"2022","unstructured":"Baldassi D, et al. Inhibition of SARS-CoV-2 replication in the lung with siRNA\/VIPER polyplexes. J Control Release. 2022;345:661\u201374. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.051.","journal-title":"J Control Release"},{"key":"1659_CR30","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown KM, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022;40:1500\u20138. https:\/\/doi.org\/10.1038\/s41587-022-01334-x.","journal-title":"Nat Biotechnol"},{"key":"1659_CR31","doi-asserted-by":"publisher","unstructured":"O\u2019Carroll M et al. Late Breaking Abstract - A first-in-human study of ARO-RAGE, an RNAi therapy designed to silence pulmonary RAGE expression. Eur Respir J 62, OA2601 https:\/\/doi.org\/10.1183\/13993003.congress-2023.OA2601","DOI":"10.1183\/13993003.congress-2023.OA2601"},{"key":"1659_CR32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/nar\/gkab1248","volume":"50","author":"S Ambike","year":"2022","unstructured":"Ambike S, et al. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res. 2022;50:333\u201349. https:\/\/doi.org\/10.1093\/nar\/gkab1248.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR33","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/ddr.21571","volume":"80","author":"K Dua","year":"2019","unstructured":"Dua K, et al. The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress. Drug Dev Res. 2019;80:714\u201330. https:\/\/doi.org\/10.1002\/ddr.21571.","journal-title":"Drug Dev Res"},{"key":"1659_CR34","doi-asserted-by":"publisher","unstructured":"Kasahara D et al. A Clinical-Stage Inhaled RNAi Therapeutic For Pulmonary Inflammation Mediates Durable RAGE Silencing In Nonhuman Primates (NHP). Eur Respir J 62, PA1289 https:\/\/doi.org\/10.1183\/13993003.congress-2023.PA1289","DOI":"10.1183\/13993003.congress-2023.PA1289"},{"key":"1659_CR35","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nm1280","volume":"11","author":"BJ Li","year":"2005","unstructured":"Li BJ, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med. 2005;11:944\u201351. https:\/\/doi.org\/nm1280.","journal-title":"Nat Med"},{"key":"1659_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12539-015-0266-9","volume":"7","author":"SM Nur","year":"2015","unstructured":"Nur SM, Hasan MA, Amin MA, Hossain M, Sharmin T. Design of Potential RNAi (miRNA and siRNA) Molecules for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Gene Silencing by Computational Method. Interdiscip Sci. 2015;7:257\u201365. https:\/\/doi.org\/10.1007\/s12539-015-0266-9.","journal-title":"Interdiscip Sci"},{"key":"1659_CR37","doi-asserted-by":"publisher","first-page":"e15298","DOI":"10.15252\/emmm.202115298","volume":"14","author":"YC Chang","year":"2022","unstructured":"Chang YC, et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol Med. 2022;14:e15298. https:\/\/doi.org\/10.15252\/emmm.202115298.","journal-title":"EMBO Mol Med"},{"key":"1659_CR38","doi-asserted-by":"publisher","first-page":"e2219523120","DOI":"10.1073\/pnas.2219523120","volume":"120","author":"VN Hariharan","year":"2023","unstructured":"Hariharan VN, et al. Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2023;120:e2219523120. https:\/\/doi.org\/10.1073\/pnas.2219523120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1659_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.05.004","author":"A Idris","year":"2021","unstructured":"Idris A, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.004.","journal-title":"Mol Ther"},{"key":"1659_CR40","doi-asserted-by":"publisher","first-page":"105677","DOI":"10.1016\/j.antiviral.2023.105677","volume":"217","author":"E Bowden-Reid","year":"2023","unstructured":"Bowden-Reid E, et al. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2. Antiviral Res. 2023;217:105677. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105677.","journal-title":"Antiviral Res"},{"key":"1659_CR41","doi-asserted-by":"publisher","first-page":"105879","DOI":"10.1016\/j.antiviral.2024.105879","volume":"226","author":"B Tolksdorf","year":"2024","unstructured":"Tolksdorf B, et al. Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses. Antiviral Res. 2024;226:105879. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105879.","journal-title":"Antiviral Res"},{"key":"1659_CR42","doi-asserted-by":"publisher","first-page":"D33","DOI":"10.1093\/nar\/gkad1044","volume":"52","author":"EW Sayers","year":"2024","unstructured":"Sayers EW, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2024;52:D33\u201343. https:\/\/doi.org\/10.1093\/nar\/gkad1044.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1128\/CMR.00102-14","volume":"28","author":"JF Chan","year":"2015","unstructured":"Chan JF, et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015;28:465\u2013522. https:\/\/doi.org\/10.1128\/CMR.00102-14.","journal-title":"Clin Microbiol Rev"},{"key":"1659_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12859-023-05245-9","volume":"24","author":"C Camacho","year":"2023","unstructured":"Camacho C, Boratyn GM, Joukov V, Vera Alvarez R, Madden TL. ElasticBLAST: accelerating sequence search via cloud computing. BMC Bioinformatics. 2023;24:117. https:\/\/doi.org\/10.1186\/s12859-023-05245-9.","journal-title":"BMC Bioinformatics"},{"key":"1659_CR45","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.18471403","author":"J Vogler","year":"2026","unstructured":"Vogler J, et al. Data and code for Comparative genomics identifies small interfering RNA with activity against all five human Betacoronaviruses [Data set]. Zenodo. 2026. https:\/\/doi.org\/10.5281\/zenodo.18471403.","journal-title":"Zenodo"},{"key":"1659_CR46","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","volume":"30","author":"K Katoh","year":"2013","unstructured":"Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30:772\u201380. https:\/\/doi.org\/10.1093\/molbev\/mst010.","journal-title":"Mol Biol Evol"},{"key":"1659_CR47","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1093\/bioinformatics\/btz305","volume":"35","author":"AM Kozlov","year":"2019","unstructured":"Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35:4453\u20135. https:\/\/doi.org\/10.1093\/bioinformatics\/btz305.","journal-title":"Bioinformatics"},{"key":"1659_CR48","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","volume":"34","author":"J Hadfield","year":"2018","unstructured":"Hadfield J, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34:4121\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/bty407.","journal-title":"Bioinformatics"},{"key":"1659_CR49","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1093\/nar\/gks797","volume":"41","author":"RL Boudreau","year":"2013","unstructured":"Boudreau RL, et al. siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res. 2013;41:e9. https:\/\/doi.org\/10.1093\/nar\/gks797.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR50","doi-asserted-by":"publisher","unstructured":"Sauerhering L, et al. Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-lambda in vitro and in mice. Eur Respir J. 2020;56. https:\/\/doi.org\/10.1183\/13993003.01826-2019.","DOI":"10.1183\/13993003.01826-2019"},{"key":"1659_CR51","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/nar\/gkg393","volume":"31","author":"F Czauderna","year":"2003","unstructured":"Czauderna F, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31:2705\u201316. https:\/\/doi.org\/10.1093\/nar\/gkg393.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR52","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/nar\/gki312","volume":"33","author":"Q Du","year":"2005","unstructured":"Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 2005;33:1671\u20137. https:\/\/doi.org\/10.1093\/nar\/gki312.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR53","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","volume":"181","author":"D Kim","year":"2020","unstructured":"Kim D, et al. The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020;181:914\u201321. https:\/\/doi.org\/10.1016\/j.cell.2020.04.011. e910.","journal-title":"Cell"},{"key":"1659_CR54","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-020-2294-9","volume":"582","author":"N Thi","year":"2020","unstructured":"Thi N, Thao T, et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020;582:561\u20135. https:\/\/doi.org\/10.1038\/s41586-020-2294-9.","journal-title":"Nature"},{"key":"1659_CR55","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMc2501792","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Witteles RM, Eraly SA. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. Reply. N Engl J Med. 2025;392:1870\u20131. https:\/\/doi.org\/10.1056\/NEJMc2501792.","journal-title":"N Engl J Med"},{"key":"1659_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023;389:228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2208391.","journal-title":"N Engl J Med"},{"key":"1659_CR57","doi-asserted-by":"publisher","first-page":"e084521","DOI":"10.1002\/alz.084521","volume":"20","author":"S Cohen","year":"2024","unstructured":"Cohen S, et al. Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN-APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2024;20:e084521. https:\/\/doi.org\/10.1002\/alz.084521.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1659_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","volume":"26","author":"DJ Foster","year":"2018","unstructured":"Foster DJ, et al. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates. Mol Ther. 2018;26:708\u201317. https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.021.","journal-title":"Mol Ther"},{"key":"1659_CR59","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic, siRNA: State-of-the-Art and Future Perspectives. BioDrugs. 2022;36:549\u201371. https:\/\/doi.org\/10.1007\/s40259-022-00549-3.","journal-title":"BioDrugs"},{"key":"1659_CR60","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1093\/nar\/gkp835","volume":"37","author":"H Huang","year":"2009","unstructured":"Huang H, et al. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res. 2009;37:7560\u20139. https:\/\/doi.org\/10.1093\/nar\/gkp835.","journal-title":"Nucleic Acids Res"},{"key":"1659_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nmeth854","volume":"3","author":"A Birmingham","year":"2006","unstructured":"Birmingham A, et al. 3\u2019 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods. 2006;3:199\u2013204. https:\/\/doi.org\/10.1038\/nmeth854.","journal-title":"Nat Methods"},{"key":"1659_CR62","doi-asserted-by":"publisher","first-page":"e29783","DOI":"10.1002\/jmv.29783","volume":"96","author":"M Volcic","year":"2024","unstructured":"Volcic M, et al. Attenuated replication and damaging effects of SARS-CoV-2 Omicron variants in an intestinal epithelial barrier model. J Med Virol. 2024;96:e29783. https:\/\/doi.org\/10.1002\/jmv.29783.","journal-title":"J Med Virol"},{"key":"1659_CR63","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41467-024-45274-3","volume":"15","author":"T Tamura","year":"2024","unstructured":"Tamura T, et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Nat Commun. 2024;15:1176. https:\/\/doi.org\/10.1038\/s41467-024-45274-3.","journal-title":"Nat Commun"},{"key":"1659_CR64","doi-asserted-by":"publisher","first-page":"11255","DOI":"10.1128\/JVI.00947-10","volume":"84","author":"K Pyrc","year":"2010","unstructured":"Pyrc K, et al. Culturing the unculturable: human coronavirus HKU1 infects, replicates, and produces progeny virions in human ciliated airway epithelial cell cultures. J Virol. 2010;84:11255\u201363. https:\/\/doi.org\/10.1128\/JVI.00947-10.","journal-title":"J Virol"},{"key":"1659_CR65","doi-asserted-by":"publisher","unstructured":"Lau SKP, et al. Discovery and Sequence Analysis of Four Deltacoronaviruses from Birds in the Middle East Reveal Interspecies Jumping with Recombination as a Potential Mechanism for Avian-to-Avian and Avian-to-Mammalian Transmission. J Virol. 2018;92. https:\/\/doi.org\/10.1128\/JVI.00265-18.","DOI":"10.1128\/JVI.00265-18"},{"key":"1659_CR66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2164-6-70","volume":"6","author":"R Wernersson","year":"2005","unstructured":"Wernersson R, et al. Pigs in sequence space: a 0.66X coverage pig genome survey based on shotgun sequencing. BMC Genomics. 2005;6:70. https:\/\/doi.org\/10.1186\/1471-2164-6-70.","journal-title":"BMC Genomics"},{"key":"1659_CR67","doi-asserted-by":"publisher","unstructured":"Wang Q et al. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. Cell 182, 417\u2013428 e413 (2020). https:\/\/doi.org\/10.1016\/j.cell.2020.05.034","DOI":"10.1016\/j.cell.2020.05.034"},{"key":"1659_CR68","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1089\/nat.2014.0494","volume":"24","author":"JH Park","year":"2014","unstructured":"Park JH, Hong SW, Yun S, Lee DK, Shin C. Effect of siRNA with an asymmetric RNA\/dTdT overhang on RNA interference activity. Nucleic Acid Ther. 2014;24:364\u201371. https:\/\/doi.org\/10.1089\/nat.2014.0494.","journal-title":"Nucleic Acid Ther"},{"key":"1659_CR69","doi-asserted-by":"publisher","first-page":"15991","DOI":"10.1074\/jbc.M300714200","volume":"278","author":"EA Bohula","year":"2003","unstructured":"Bohula EA, et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem. 2003;278:15991\u20137. https:\/\/doi.org\/10.1074\/jbc.M300714200.","journal-title":"J Biol Chem"},{"key":"1659_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone B, Urakova N, Snijder EJ, Campbell EA. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol. 2022;23:21\u201339. https:\/\/doi.org\/10.1038\/s41580-021-00432-z.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1659_CR71","doi-asserted-by":"publisher","unstructured":"Fan Y, Yang Z. Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14061193.","DOI":"10.3390\/pharmaceutics14061193"},{"key":"1659_CR72","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jconrel.2022.09.021","volume":"351","author":"CM Zimmermann","year":"2022","unstructured":"Zimmermann CM, et al. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release. 2022;351:137\u201350. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.021.","journal-title":"J Control Release"},{"key":"1659_CR73","doi-asserted-by":"publisher","unstructured":"Qiu M, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022;119. https:\/\/doi.org\/10.1073\/pnas.2116271119.","DOI":"10.1073\/pnas.2116271119"},{"key":"1659_CR74","doi-asserted-by":"publisher","unstructured":"O'Carroll MR, et al. A first-in-human study of ARO-RAGE, a novel inhaled RNA-interference therapy for asthma. In: A34. LATE BREAKING ABSTRACTS IN ASTHMA AND ALLERGIC INFLAMMATION. Am Thorac Soc. 2024;S1:A1376. https:\/\/doi.org\/10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1376.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A1376"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01659-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01659-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01659-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:15Z","timestamp":1781649075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01659-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01659-1","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}